Inventiva (NASDAQ:IVA) Sees Large Volume Increase Following Analyst Upgrade

Key Points

• Inventiva shares saw a 21% surge in trading volume after Truist Financial raised its price target from $13 to $18 while maintaining a buy rating. The stock traded at $3.5350, up from a prior close of $3.46.
• Analyst sentiment is generally positive, with a consensus rating of “Buy” and an average price target of $15.86, despite one sell rating.
• Institutional investors have increased exposure to Inventiva, with hedge funds and other institutions owning 19.06% of the company. The clinical-stage biotech is developing lanifibranor, a late-stage treatment candidate for MASH.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares saw unusually-high trading volume on Friday after Truist Financial raised their price target on the stock from $13.00 to $18.00. Truist Financial currently has a buy rating on the stock. Approximately 1,016,893 shares traded hands during trading, an increase of 21% from the previous session's volume of 837,308 shares. The stock last traded at $3.5350 and had previously closed at $3.46.

A number of other brokerages also recently issued reports on IVA. Piper Sandler reissued an "overweight" rating on shares of Inventiva in a research note on Wednesday, September 16th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an "overweight" rating for the company. Guggenheim boosted their target price on Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a research report on Tuesday, September 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $15.86.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IVA. Propel Bio Management LLC purchased a new stake in Inventiva in the fourth quarter worth about $4,650,000. Seven Fleet Capital Management LP purchased a new position in Inventiva during the first quarter valued at approximately $1,111,000. Eventide Asset Management LLC purchased a new position in Inventiva during the fourth quarter valued at approximately $1,155,000. NEXTBio Capital Management LP bought a new position in Inventiva in the fourth quarter worth approximately $6,039,000. Finally, Engineers Gate Manager LP lifted its holdings in Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after buying an additional 43,280 shares during the period. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Trading Up 4.2%

The business has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $4.67.

Inventiva (NASDAQ:IVA - Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The business had revenue of $0.75 million during the quarter. As a group, equities analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current year.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.